Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2019 10:54 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

WATERTOWN, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
November 14, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

WATERTOWN, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
November 07, 2019 06:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

– U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers...
November 04, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint...
November 01, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
October 24, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
October 02, 2019 16:05 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
September 27, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
September 26, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
September 09, 2019 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...